Hormonal
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide facilitate weight loss and glycemic control by delaying gastric emptying, stimulating insulin release, and suppressing glucagon secretion.
If you have obesity and struggle to maintain weight loss through diet and exercise alone, GLP-1 medications like liraglutide or semaglutide are FDA-approved options. They work by mimicking a hormone that regulates appetite and digestion. You will need to commit to lifestyle changes alongside the medication, as the drugs are adjuncts, not replacements. Be prepared for potential gastrointestinal side effects, which are common but often subside.
Liraglutide decreases body weight (BM), delays gastric emptying, stimulates insulin release, reduces glucagon release, and lowers BM by allowing the proper management of calorie intake, thereby leading to improved control of blood glucose and enhanced weight management.
Why this rating
The paper cites multiple FDA approvals and large-scale clinical trials (e.g., 4,000+ subjects for semaglutide), indicating high-quality evidence.
Source
Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
Alexander C. Martins et al. · Exploration of Drug Science · 2024
DOI 10.37349/eds.2024.00039
More from this paper
- Semaglutide demonstrates superior weight loss and glycemic control compared to other GLP-1RAs like liraglutide and dulaglutide, with weight loss ranging from 10% to over 20%.Good
- Tirzepatide, a dual GIP and GLP-1 receptor agonist, provides superior weight loss and metabolic improvements compared to selective GLP-1RAs, insulin, and placebo.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →